Clinical trial
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in…
NCT02326298 · UCB Biopharma S.P.R.L., Industry · Completed
Key facts
| NCT number | NCT02326298 |
|---|---|
| Title | An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) |
| Official title | A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| Acronym | CIMPASI-1 |
| Lead sponsor | UCB Biopharma S.P.R.L., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis, Plaque Psoriasis |
| Intervention type | Biological, Other |
| Interventions | Certolizumab Pegol, Placebo |
| Enrollment | 234 |
| Start date | Dec 16, 2014 |
| Primary completion | Mar 8, 2016 |
| Completion | Oct 24, 2018 |
| First posted | Dec 29, 2014 |
| Last update posted | Nov 7, 2019 |
| Countries | Canada, Czechia, Germany, Hungary, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: